PD-L1 Expression in Triple-negative Breast Cancer-a Comparative Study of 3 Different Antibodies.
Tatjana VlajnicFabienne BaurSavas D SoysalWalter P WeberSalvatore PiscuoglioSimone MuenstPublished in: Applied immunohistochemistry & molecular morphology : AIMM (2022)
Our results show that the 3 PD-L1 antibodies identify different TNBC patient subgroups as PD-L1 positive and, therefore cannot be used interchangeably. Additional studies are needed to further investigate the use and impact of different PD-L1 antibody clones for predictive selection of TNBC patients for treatment with immune checkpoint inhibitors.